Parkinson disease. Parkinson's disease
Conditions
Interventions
Intervention 1: Intervention group 1: Patients receiving citalopram 10 mg daily for the first week and then 20 mg daily. Intervention 2: Intervention group 2: Patients receiving pramipexole 0.09 mg tw
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: Controlled disease with monotheraphy with Levodopa
Exclusion criteria
Exclusion criteria: Cognitive disorders Psychotic disorders and suicidal thought or attempt Use of antipsychotics, anticholinergics, dopamine agonists and other psychological drugs and therapies Use of metoclopramide, methyldopa, methylphenidate, reserpine, flunarizine, Cinnarizine and amphetamine derivatives within the past 3 months History of malignant melanoma History of previous deep brain stimulation surgery Pregnancy Lactating using contraceptive drugs “Off” period for greater than 50% of the day
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Beck depression inventory total score. Timepoint: Assessment of depression score in Beck depression inventory at baseline (before intervention) and 8 weeks after starting pramipexole or citalopram. Method of measurement: Beck depression inventory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life score. Timepoint: Assessment of quality of life score with Parkinson's Disease Questionnaire at baseline (before intervention) and 8 weeks after starting pramipexole or citalopram. Method of measurement: Parkinson's Disease Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEhsan Ziaei
Esfahan University of Medical Sciences
Outcome results
None listed